Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | AFM13 |
| Trade Name | |
| Synonyms | AFM 13|AFM-13|Acimtamig |
| Drug Descriptions |
AFM13 is a tetravalent bispecific antibody targeting CD30 and CD16A, which recruits CD16A-expressing NK cells to CD30-expressing tumor cells, potentially inducing tumor cell killing and enhanced antitumor immune response (PMID: 26231785, PMID: 33986022). |
| DrugClasses | |
| CAS Registry Number | 2738880-26-5 |
| NCIT ID | C94219 |
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| AB-101 + AFM13 | AB-101 AFM13 | 0 | 1 |
| AFM13 | AFM13 | 0 | 3 |
| AFM13 + Cyclophosphamide + Fludarabine | AFM13 Cyclophosphamide Fludarabine | 0 | 0 |
| AFM13 + Pembrolizumab | AFM13 Pembrolizumab | 0 | 1 |